M any studies in humans and in experimental models have shown that atherosclerosis is characterized by inflammatory lesions of the vessel walls, with the presence of numerous components of the immune system. 1 The complement system, which forms an important link between innate and adaptive immunity, can be activated by the classical (CP), alternative (AP), or lectin (LP) pathway, all of which converge on C3 activation with subsequent cleavage of C5 and generation of the terminal complement complex (TCC) (C5b-9). 2 The AP is continually activated at a low level in plasma by the "tickover" mechanism, in which spontaneous hydrolysis of the thioester bond in native C3 generates a C3b-like molecule, C3(H 2 O). Factor B then binds to this C3b-like molecule with subsequent enzymatic cleavage by factor D to form the C3bBb complex, which serves as a C3 convertase to generate more C3b. 3, 4 It is now well recognized that the amplification loop of the AP plays a central role in the downstream effects of complement activation. 5
Clinical Perspective on p 1956
Several previous studies have investigated the role of the complement system in the pathogenesis of atherosclerosis with seemingly contradictory results. Rabbits deficient in C6 fed a cholesterol-rich diet were shown to develop less atherosclerosis than C6-sufficient animals, indicative of a harmful effect of the TCC. 6 However, when the role of TCC was studied with the use of C5-deficient mice, which are unable to form TCC, on the apolipoprotein E-deficient (Apoe Ϫ/Ϫ ) background, no significant differences were found compared with control Apoe Ϫ/Ϫ mice. 7 In contrast, increased atherosclerotic lesion size was detected in low-density lipoprotein receptor-deficient mice (Ldlr Ϫ/Ϫ ) with CP (C1qdeficient mice) 8 or LP (MBL-A-and MBL-C-double-deficient mice) 9 abnormalities, probably reflecting known protective roles of these pathways in the disposal of apoptotic cells and other tissue debris. 10, 11 The disparate effects of upstream and terminal complement components are further supported by recent studies in mice deficient in CD59, the membrane-bound regulator of TCC, that have revealed a protective role of CD59 in atherosclerosis on either Apoe Ϫ/Ϫ or Ldlr Ϫ/Ϫ backgrounds. [12] [13] [14] Moreover, experiments on the C3 regulator CD55 (also known as decay accelerating factor [DAF]) showed exacerbation of atherosclerotic lesions in DAF-deficient Ldlr Ϫ/Ϫ mice, although this was not seen in DAF-deficient Apoe Ϫ/Ϫ mice. 14, 15 In the case of C3, C3 deficiency on the Ldlr Ϫ/Ϫ background resulted in larger lesions with increased lipid deposition and impaired lesion development beyond the foam cell stage, 16 whereas on the Apoe Ϫ/Ϫ /Ldlr Ϫ/Ϫ background, it also led to slightly larger lesions but with a more atherogenic lipid profile. 17 Taken together, these previous reports indicate that the complement system plays a dual role in atherogenesis, with a protective effect provided by the CP and LP and a detrimental effect triggered by the terminal pathway.
The role of the AP in atherosclerosis remains largely unknown. Notably, Apoe Ϫ/Ϫ /Ldlr Ϫ/Ϫ mice lacking factor B (Bf Ϫ/Ϫ ) did not show any changes in lipid levels or lesion size compared with the Apoe Ϫ/Ϫ /Ldlr Ϫ/Ϫ control mice, implying that the AP does not play an important role in that model. 17 In the present study, we sought to investigate the role of the AP using factor B-deficient mice crossed with Ldlr Ϫ/Ϫ (Bf Ϫ/Ϫ / Ldlr Ϫ/Ϫ ) animals. We found that administration of lipopolysaccharide or a 12-week period of high-fat (HF) diet, experimental conditions known to be linked to atherogenesis, resulted in accelerated atherosclerotic lesion formation in the Ldlr Ϫ/Ϫ mice, whereas the Bf Ϫ/Ϫ /Ldlr Ϫ/Ϫ animals were protected. The protective effects of factor B deficiency were paralleled by marked reductions in systemic and local complement activation. These findings taken together indicate that the amplification loop of the AP plays a key role in endotoxin-and diet-induced exacerbation of atherosclerosis in the Ldlr Ϫ/Ϫ mouse model, and they help to establish a clearer picture of the bifunctional role of the complement system in atherosclerosis.
Methods

Mice
Ldlr Ϫ/Ϫ mice (Jackson Laboratories, Bar Harbor, Me) were crossbred with Bf Ϫ/Ϫ mice generated as described previously. 18 All strains had been backcrossed onto the C57BL/6 background for 10 generations before creating double-knockout mice. Mice were maintained in a specific pathogen-free environment and studied according to institutional guidelines.
Endotoxin Model
Twelve-week-old Bf Ϫ/Ϫ /Ldlr Ϫ/Ϫ and Ldlr Ϫ/Ϫ female mice received an intraperitoneal injection of either lipopolysaccharide (50 g; Escherichia coli serotype 055:B5, Sigma, St Louis, Mo) in 200 L of phosphate-buffered saline (PBS) or 200 L of PBS once a week for 10 weeks. Throughout the procedure, the animals were fed a low-fat (LF) diet. At 22 weeks of age, the mice were analyzed as described below.
Diet-Induced Atherosclerosis
The experimental groups consisted of female Bf -Ϫ/Ϫ /Ldlr Ϫ/Ϫ and Ldlr Ϫ/Ϫ mice, which were transferred onto either a LF or a HF diet at 10 weeks of age. The compositions of the diets were reported previously. 8 Mice were euthanized at 22 weeks of age for analysis.
Plasma Lipid and Lipoprotein Analysis
Serum total triglyceride and cholesterol levels were measured enzymatically on each individual mouse with the use of Kit Infinity TR13421/2350-250 and Kit Infinity TR22421/2780-250, respectively (MediMark, Grenoble, France). Cholesterol and triglyceride distribution in plasma lipoprotein fractions was determined on pooled sera by fast performance liquid chromatography gel filtration on a Superose 6 HR 10/30 size-exclusion column. 19 
Atherosclerotic Lesion Analysis
After 12 weeks of diet, mice were fasted overnight, euthanized by CO 2 inhalation, and weighed, and blood was collected for serum analyses. Hearts and aortae were perfused as described previously. 19 Each aorta was cut longitudinally and photographed with an Olympus DP50 camera. Atherosclerosis was quantified by en face plaque analysis with the use of ImagePro software (version 4.5; Media Cybernetics, Silver Spring, Md) in a blind fashion and expressed as percentage of total aortic area. Further details on the aortic root analysis are provided in Methods in the online-only Data Supplement.
Quantification and Immunohistochemistry of Atherosclerotic Lesions
Immunohistochemistry was performed by standard procedures. Sections were stained for macrophages (anti-CD68 antibody) (Serotec, Kidlington, UK) and vascular smooth muscle cells (VSMCs) (alkaline phosphatase/anti-␣-smooth actin antibody, clone 1A4) (Sigma-Aldrich, Poole, UK) followed by biotinylated immunoglobulin G (IgG) secondary antibodies (BD Biosciences, Oxford, UK) and streptavidin-horseradish peroxidase (Dako, Ely, UK) with the use of 3,3Ј-diaminobenzidine tetrahydrochloride as substrate. Lesional complement C3d was measured with a biotinylated goat anti-mouse C3d antibody (R&D Systems, Abingdon, UK) followed by streptavidin-horseradish peroxidase (Dako, Ely, UK) with 3,3Јdiaminobenzidine as substrate. C3d staining was quantified with the use of ImagePro software and expressed as percentage of lesion area staining positive. The methods applied for lesional C3d and IgG staining are described in the online-only Data Supplement.
Measurement of C3 and C3a Levels
C3 levels were measured by enzyme-linked immunosorbent assay as reported previously. Results were quantified by reference to a standard curve containing a known quantity of C3 (Calbiochem, Nottingham, UK).
C3a levels were detected by the same protocol but with the addition of biotinylated rat anti-mouse C3a (BD Biosciences, Oxford, UK). Results were quantified by reference to a standard curve containing a known quantity of C3a (BD Biosciences).
Determination of Antibodies Against Oxidized Low-Density Lipoprotein
Human low-density lipoprotein (LDL) was isolated as described previously. 19 Oxidized LDL (OxLDL) was prepared by incubating LDL with either freshly synthesized malondialdehyde or CuSO 4 to generate malondialdehyde-LDL and copper-oxidized LDL (CuOx-LDL). Detection of anti-malondialdehyde-LDL and anti-CuOxLDL antibodies was performed as described. 19 
Statistical Analysis
Results were analyzed with the use of Graphpad Prism version 3.0 (Graphpad Software, San Diego, Calif). When the data were not normally distributed, nonparametric statistical tests were used, and results are expressed as median (interquartile range). The Mann-Whitney U test was used to compare 2 groups. Normally distributed data were expressed as meanϮSEM and compared by use of an unpaired 2-tailed Student t test. P values were considered significant at PϽ0.05.
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results
Effects of Factor B Deficiency on Diet-Induced Atherosclerosis
Initially, we explored the involvement of the AP in dietaccelerated atherosclerosis. The characteristics of the experimental groups are illustrated in the Table. No significant differences were observed between Ldlr Ϫ/Ϫ and Bf Ϫ/Ϫ / Ldlr Ϫ/Ϫ cohorts in final body weight, total serum triglyceride levels, or triglyceride lipoprotein fast performance liquid chromatography profiles on LF or HF diet (Table and Figure  1A ). However, Bf Ϫ/Ϫ /Ldlr Ϫ/Ϫ mice had significantly lower serum cholesterol levels compared with Ldlr Ϫ/Ϫ animals on a HF diet (Bf Ϫ/Ϫ /Ldlr Ϫ/Ϫ , 25.2Ϯ0.9 mmol/L, nϭ14; Ldlr Ϫ/Ϫ , 40.5Ϯ1.3 mmol/L; nϭ17; meanϮSEM, PϽ0.0001) (Table) . Cholesterol lipid profiles also showed significantly reduced amounts of very-low-density lipoprotein and LDL (Ϸ1.5-fold lower) in the Bf Ϫ/Ϫ /Ldlr Ϫ/Ϫ mice compared with Ldlr Ϫ/Ϫ animals ( Figure 1B ).
Atherosclerotic plaque burden was quantified in Bf Ϫ/Ϫ / Ldlr Ϫ/Ϫ mice and compared with Ldlr Ϫ/Ϫ mice, as described in Methods. Whereas the analysis of the whole aorta en face atherosclerotic lesion area showed no significant differences between the 2 experimental groups on the LF or HF diet ( Figure I in the online-only Data Supplement), a substantial decrease in atherosclerotic lesion area fraction was found at the aortic root in the Bf Ϫ/Ϫ /Ldlr Ϫ/Ϫ mice fed a HF diet ( Figure 2 (Figure 2 ). There was no significant difference in aortic root areas between the 2 experimental cohorts on the LF diet ( Figure 2) .
Consistent with the differences in aortic root lesion size, HF diet-fed Bf Ϫ/Ϫ /Ldlr Ϫ/Ϫ mice had fewer complex athero-sclerotic plaques than Ldlr Ϫ/Ϫ mice. Quantification of the lesional ␣-actin-positive cells showed an Ϸ1.8-fold decrease in the Bf Ϫ/Ϫ /Ldlr Ϫ/Ϫ mice (Bf Ϫ/Ϫ /Ldlr Ϫ/Ϫ , as follows: 7.19%, 3.71% to 11.5%, nϭ14; Ldlr Ϫ/Ϫ , 13.12%, 9.12% to 16.7%, nϭ17; Pϭ0.004) ( Figure 3A and Figure Confocal staining of aortic root lesions for C3d as a marker of local complement activation showed a diffuse distribution but with increased positivity in endothelium, foam cells, and debris in the lipid core ( Figure IIC in the online-only Data Supplement) and was positive over a wider fraction of plaque area in Ldlr Ϫ/Ϫ mice fed a HF diet compared with the LF diet (HF: Ldlr Ϫ/Ϫ , 8.90%, 6.2% to 12.07%, nϭ14; LF: Ldlr Ϫ/Ϫ , 2.5%, 0.82% to 5.42%, nϭ13; Pϭ0.0001), indicating an effect of diet on local complement activation. Factor B deficiency decreased the percentage area of C3d staining in HF-fed diet (Bf Ϫ/Ϫ /Ldlr Ϫ/Ϫ , 2.58%, 1.41% to 3.06%, nϭ14; Ldlr Ϫ/Ϫ , 8.90%, 6.2% to 12.07%, nϭ14; PϽ0.0001) ( Figure  3A and 3B). No differences were detected between the LF diet-fed groups ( Figure 3A and 3B ). There was no significant difference between Ldlr Ϫ/Ϫ and Bf Ϫ/Ϫ /Ldlr Ϫ/Ϫ mice on either diet in IgG deposition in aortic root lesions (data not shown).
We then quantified complement activation in the circulation. On the LF diet, the 2 experimental cohorts had similar g/mL, nϭ17; PϽ0.0001) ( Figure 4A ). As expected, the C3a levels were markedly increased only in the HF diet-fed Ldlr Ϫ/Ϫ mice (PϽ0.0001), reflecting the proinflammatory milieu created by hyperlipidemia ( Figure 4B) . Thus, the reduction in aortic root lesional C3d in Bf Ϫ/Ϫ /Ldlr Ϫ/Ϫ mice demonstrated in Figure 3 could not be explained by greater systemic complement activation and subsequent depletion.
Effect of Factor B Deficiency on Lipopolysaccharide-Induced Atherosclerosis
The reduction in aortic root lesional C3d in Bf Ϫ/Ϫ /Ldlr Ϫ/Ϫ mice strongly suggested that reduced local complement activation contributed to the difference in aortic root lesion size between Ldlr Ϫ/Ϫ and Bf Ϫ/Ϫ /Ldlr Ϫ/Ϫ mice fed a HF diet. However, the reduced serum cholesterol levels in HF-fed Bf Ϫ/Ϫ /Ldlr Ϫ/Ϫ mice remained a possible confounding factor. We therefore addressed the role of the alternative pathway in a separate model in which atherosclerosis is accelerated by lipopolysaccharide rather than by a HF diet. 20, 21 Accordingly, we injected lipopolysaccharide or PBS weekly into mice fed a LF diet for a period of 10 weeks before euthanasia. No significant differences were observed between Ldlr Ϫ/Ϫ and Bf Ϫ/Ϫ /Ldlr Ϫ/Ϫ mice, whether injected with lipopolysaccharide or PBS, in final body weight ( Table I in the online-only Data Supplement). Furthermore, importantly, lipopolysaccharide administration had no effect on total cholesterol or triglyceride levels ( Table I in In Ldlr Ϫ/Ϫ mice, lipopolysaccharide administration increased whole aorta en face and aortic root atherosclerotic lesion area by Ϸ5.9and 4.3-fold, respectively, as shown by the comparison between PBS-and lipopolysaccharide-treated animals (en face: PBS, medianϭ0.78%, interquartile rangeϭ0.67% to 1.72%, nϭ4; lipopolysaccharide, 4.67%, 1.67% to 6.93%, nϭ10; Pϭ0.024; aortic root lesion fraction area: PBS, 5.16%, 2.84% to 7.28%, nϭ4; lipopolysaccharide, 22.53%, 17.31% to 25.25%, nϭ10; Pϭ0.002) ( Figure 5 ). In contrast, lipopolysaccharide did not alter the atherosclerotic lesion area in the Bf Ϫ/Ϫ /Ldlr Ϫ/Ϫ mice, as shown by comparison with PBS-treated Bf -Ϫ/Ϫ /Ldlr Ϫ/Ϫ mice ( Figure 5 ). In consequence, whole aorta en face atherosclerotic lesion area analysis showed a significant difference between lipopolysaccharide-treated groups (Bf -Ϫ/Ϫ /Ldlr Ϫ/Ϫ , 0.83%, 0.38% to 2.06%, nϭ9; Ldlr Ϫ/Ϫ , 4.67%, 1.67% to 6.93%, nϭ10; Pϭ0.004) ( Figure 5C ). Differences between groups in aortic root lesion size paralleled the differences in en face aortic lesion area (aortic root lesion fraction: Bf -Ϫ/Ϫ /Ldlr Ϫ/Ϫ , 7.85%, 4.93% to 15.24%, nϭ9; Ldlr Ϫ/Ϫ , 22.53%, 17.36% to 25.25%, nϭ10; Pϭ0.0009) ( Figure 5B and 5D) .
Consistent with the decreased lesion size, the analysis of lesion composition revealed reduced complexity in lipopolysaccharide-treated Bf -Ϫ/Ϫ /Ldlr Ϫ/Ϫ mice, as judged by the significant decrease in percentage of ␣-actin-positive lesional VSMCs (Bf -Ϫ/Ϫ /Ldlr Ϫ/Ϫ , 11.34%, 2.38% to 14.78%, nϭ9; Ldlr Ϫ/Ϫ , 16.0%, 13.17% to 28.34%, nϭ10; Pϭ0.024) ( Figure 6A ). This fall in VSMCs was accompanied by a reciprocal increase in proportional macrophage content (Bf -Ϫ/Ϫ / Ldlr Ϫ/Ϫ , 87.23%, 83.37% to 98.01%, nϭ9; Ldlr Ϫ/Ϫ , 80.0%, 63.46% to 86.15%, nϭ10; Pϭ0.019), associated with a reduction in overall lesion size ( Figure 6B ). IgG deposition within lesions did not differ significantly between the lipopolysaccharide-treated groups (Figure 6C ), whereas quantification of lesional C3d revealed a 2.9-fold decrease in the fraction area staining for C3d in Bf -Ϫ/Ϫ /Ldlr Ϫ/Ϫ mice compared with Ldlr Ϫ/Ϫ mice (Bf -Ϫ/Ϫ /Ldlr Ϫ/Ϫ , 2.76%, 2.37% to 4.2%, nϭ9; Ldlr Ϫ/Ϫ , 9.85%, 7.68% to 14.06%, nϭ10; PϽ0.0001) ( Figure 6D ).
Analysis of serum C3 and C3a levels showed marked complement consumption only in lipopolysaccharide-treated Ldlr Ϫ/Ϫ mice, as demonstrated by the marked reduction of C3 levels and the striking increase in C3a levels in these animals (C3: Bf -Ϫ/Ϫ /Ldlr Ϫ/Ϫ , 435.7 g/mL, 403 to 542.7 g/mL, nϭ9; Ldlr Ϫ/Ϫ , 268.3 g/mL, 403 to 542.7 g/mL, nϭ10; Pϭ0.0006; C3a: Bf -Ϫ/Ϫ /Ldlr Ϫ/Ϫ , 1.9 g/mL, 1.3 to 2.14 g/mL, nϭ9; Ldlr Ϫ/Ϫ , 7.5 g/mL, 7.12 to 7.95 g/mL, nϭ10; PϽ0.0001) ( Figure 6E and 6F) . Thus, as with mice fed the HF diet, the reduced C3d in the lesions of Bf -Ϫ/Ϫ /Ldlr Ϫ/Ϫ mice was not due to complement depletion in the circulation. Because the complement system can influence the threshold of immune responses, we then examined whether factor B deficiency had altered the antibody response against OxLDL. No significant differences were seen between Ldlr Ϫ/Ϫ and Bf -Ϫ/Ϫ /Ldlr Ϫ/Ϫ mice following the HF diet ( Figure IV 
Discussion
Although it has long been recognized that signs of complement activation are present in atherosclerotic lesions, the overall role of the complement system has remained unclear. We now show that Ldlr Ϫ/Ϫ mice lacking factor B display a substantial decrease of lipopolysaccharide-and diet-induced atherosclerosis, with smaller and less complex lesions. The decreased lesion formation detected in Bf -Ϫ/Ϫ /Ldlr Ϫ/Ϫ mice in response to endotoxin or diet was accompanied by a marked reduction in complement activation within lesions, and this was not due to systemic C3 depletion. Overall, our data provide the first direct evidence that activation of the alternative pathway amplification loop exerts an atherogenic effect.
The observation that deposition of C5b-9 in cholesterol-fed rabbits occurs together with the accumulation of lipids in the intima and precedes the accumulation of inflammatory cells has led to the hypothesis that complement activation could be an initiating event in atherogenesis. 22 Furthermore, colocalization of C5b-9 with properdin has suggested involvement of AP activation. 23 Developing atherosclerotic lesions contain multiple potential triggers for complement activation, including enzymatically modified LDL, immobilized immunogloblins, pentraxins such as C-reactive protein, cholesterol crystals, and apoptotic/necrotic cells. Of note, enzymatically modified LDL, which is abundantly present in the deep musculoelastic layer of the intima, 24 is known to be a potent activator of the alternative pathway in vitro. 25 We found in the present study that the lack of factor B on the Ldlr Ϫ/Ϫ background led to significantly less atherosclerosis and markedly decreased complement activation in response to endotoxin or HF diet. Although these observations were confined to the use of gene-targeted animals, the results indicate that the AP amplification loop, with its ability to greatly enhance C3 activation, is necessary to mediate the vascular inflammation under these experimental conditions. Thus, one can speculate that the mechanisms responsible for the decreased atherosclerosis in Bf -Ϫ/Ϫ /Ldlr Ϫ/Ϫ mice fed a HF diet or injected with lipopolysaccharide could at least in part reflect decreased lesional C3 activation in the initial phase of plaque formation and a delay in lesion evolution. This might occur through reduced recruitment and activation of monocytes (via anaphylatoxins C3a and C5a) with subsequent reduced release of cytokines and other inflammatory mediators and reduced C5b-9 -mediated cell activation and proliferation. 26, 27 Chronic infection can be mimicked by repetitive administrations of lipopolysaccharide. The concept is clinically relevant because epidemiological studies have shown that subclinical endotoxemia constitutes a strong risk factor for the development of carotid atherosclerosis, particularly among smokers. 28 In rodents, bacterial infection and lipopolysaccharide can promote accelerated atherosclerosis, 20, 21, 29 and our findings support previous observations. Obviously, 1 mechanism by which lipopolysaccharide can accelerate atherosclerosis is by interacting with the toll-like receptor 4 and stimulating intracellular signaling events, leading to the release of proinflammatory cytokines and reactive oxygen metabolites 30 . However, our data show for the first time that atherosclerosis accelerated by lipopolysaccharide is complement dependent and requires the AP. Because lipopolysaccharide is known to directly activate the AP, 31 it seems likely that this leads to an additive or synergistic interaction with the other aforementioned local stimuli for complement activation.
Factor B deficiency led to a less atherogenic plasma lipoprotein profile on the HF diet compared with Ldlr Ϫ/Ϫ controls, with decreased serum cholesterol levels and reduced very-low-density lipoprotein and LDL cholesterol. These changes may reflect abnormalities in the lipid metabolism mediated by the C3-derived peptide C3adesArg, also known as acylation-stimulating protein (ASP), a molecule considered to be critical for triglyceride synthesis and the maintenance of metabolic homeostasis. 32, 33 However, the importance of C3adesArg/ASP in systemic lipid metabolism remains controversial, with contradictory results reported in the literature. 16, 17 Because adipocytes secrete factor B, C3, and adipsin/factor D, C3adesArg/ASP is believed to be generated mainly by the AP of complement activation. Therefore, the factor B-deficient mice, which cannot generate ASP through the proteolytic cleavage mediated by factor B and factor D, might have been expected to have lipid abnormalities similar to those reported in mice lacking C3. 16, 17 However, in HF-fed Bf -Ϫ/Ϫ /Ldlr Ϫ/Ϫ mice, we found no body weight loss and decreased fasting cholesterol levels, suggesting that energy storage and lipid homeostasis are regulated differently in these 2 complement-deficient models. C3 is present in Bf Ϫ/Ϫ /Ldlr Ϫ/Ϫ mice, and thus C3adesArg/ ASP could be generated by the activation of the CP or LP in adipose tissue and have a local effect. Consistent with this possibility, genes encoding proteins of the CP have been found to be expressed in human adipose tissue. 34 A detailed investigation of the role of the AP in energy homeostasis and metabolism is beyond the scope of the present article.
Clearly, the less atherogenic lipid profile observed in HF-fed Bf -Ϫ/Ϫ /Ldlr Ϫ/Ϫ mice is likely to have contributed to the reduced atherosclerosis development observed in these mice. However, no significant changes in lipid levels were observed in the LF-fed lipopolysaccharide-treated Bf -Ϫ/Ϫ / Ldlr Ϫ/Ϫ mice, which also developed significantly less atherosclerosis. These results support the contention that the differences we observed in the extent and phenotype of atherosclerotic lesions in Bf -Ϫ/Ϫ /Ldlr Ϫ/Ϫ mice compared with the controls are attributable to direct effects of reduced complement activation in addition to any effects of the AP on lipid metabolism. The decrease in atherosclerosis was observed only in Bf -Ϫ/Ϫ /Ldlr Ϫ/Ϫ mice on a HF diet or on a LF diet but treated with lipopolysaccharide to mimic subclinical infections. Thus, the requirement for lipopolysaccharide or a HF diet for the AP to mediate disease in vivo may be because under the low-grade atherogenic conditions modeled by the LF diet, the initiation of complement activation by the CP or LP does not produce an adequate quantity or quality of C3b deposition within lesions to activate the AP. Set beside our previous results in Ldlr Ϫ/Ϫ /C1q Ϫ/Ϫ mice showing a protective homeostatic effect of the CP in LF-fed but not in HF-fed animals, 8 the increased lesional complement activation following a HF diet or lipopolysaccharide treatment provides strong support to the idea that the AP is responsible for driving the proatherogenic effect of the complement system under more inflammatory conditions.
Our results may appear at odds with a recent study that showed that factor B deficiency had no effect on atherosclerosis development in Apoe Ϫ/Ϫ /Ldlr Ϫ/Ϫ mice. 17 However, the Apoe Ϫ/Ϫ /Ldlr Ϫ/Ϫ and Ldlr Ϫ/Ϫ models are distinct and not necessarily interchangeable. 35 In particular, it is possible that lesion development in the Apoe Ϫ/Ϫ model is less dependent on complement activation, in view of the previous failure to demonstrate protective effects of C5 deficiency in this strain. 7 Similarly, DAF deficiency in the Apoe Ϫ/Ϫ background had no effect, whereas Ldlr Ϫ/Ϫ mice lacking DAF showed increased lesion formation. 13, 15 It should also be recognized that there may be a sex difference because male mice were used in the study of Persson et al, 17 and our study was focused on females. Finally, the study of Persson et al relied on sponta- neously developing lesions and did not challenge the mice with lipopolysaccharide.
In conclusion, the data of this study highlight the potential of the AP amplification loop to have proatherogenic effects in response to diet and lipopolysaccharide. Recently, the AP has been implicated in a variety of human diseases and animal models. 4 In the majority of these conditions, the AP may serve as an amplification mechanism for C3b generation initiated by the CP and possibly LP. In agreement with this, our findings, taken together with previous reports, 8, 9 can best be explained by the CP and LP playing protective roles and the AP being more proinflammatory and proatherogenic. Thus, our murine data strongly support the rationale for therapeutic strategies aiming to inhibit the complement system by blocking the AP without interfering with the important protective roles that the complement system plays in both innate and adaptive immunity.
